ESC Professional Premium Access

Dapagliflozin improves Myocardial Flow Reserve in patients with Type 2 Diabetes: the DAPAHEART Trial.

Topic: Cardiovascular Pharmacotherapy

Congress Presentation

About the speaker

Doctor Domenico D'amario

Fondazione Policlinico Universitario A. Gemelli IRCSS, Rome (Italy)
4 presentations
0 follower

6 more presentations in this session

Absolute treatment effects of novel oral antidiabetic drugs on cardiovascular mortality and hospitalization for heart failure: a meta-analysis of digitalized individual patient outcomes

Speaker: Mr G. Wolff (Duesseldorf, DE)

Thumbnail

The gender gap in prescription pattern of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes

Speaker: Mr A. Hammer (Vienna, AT)

Thumbnail

Pharmacological selectivity of SGLT2 inhibitors and cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis

Speaker: Doctor A. Sayour (Budapest, HU)

Thumbnail

Impact of SGLT2 inhibitor on mortality and cardiovascular outcomes in patients with type 2 diabetes mellitus with left main or multivessel coronary artery disease

Speaker: Doctor D. Chipayo Gonzales (Madrid, ES)

Thumbnail

Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes patients: a propensity score-matched study

Speaker: Mr O. Chou (Hong Kong, HK)

Thumbnail

Access the full session

SGLT2 inhibitors in clinical practice

Speakers: Doctor D. D'amario, Mr G. Wolff, Mr A. Hammer, Doctor A. Sayour, Doctor D. Chipayo Gonzales...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk